As part of their recently signed agreement, Ranbaxy will be able to progress and further profile this drug candidate through preclinical studies needed to support an investigational new drug application. Ranbaxy will also be responsible for conducting phase I and phase II studies through to proof of concept. GSK will then have the option to conduct further development through to final commercialization.
The Ranbaxy and GSK alliance envisages research in a wide range of therapeutic areas of interest, including anti-infectives, metabolic disorders, respiratory and oncology.
Ranbaxy could receive over $100 million in potential milestone payments for a product developed by Ranbaxy and subsequently launched by GSK in multiple indications and up to double digit royalties on worldwide net sales.